medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 1

<< Back Next >>

Ann Hepatol 2018; 17 (1)

Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy

George N, Harrell SM, Rhodes KD, Duarte-Rojo A

Language: English
References: 50
Page: 76-84
PDF size: 236.60 Kb.


ABSTRACT

Background and aims. Practitioners treating hepatitis C (HCV) provide healthcare to a special population with high rates of substance abuse and psychiatric disorders. We investigated the psychosocial profile in HCV patients and tested what variables affect commencement of antiviral therapy. Material and methods. Recreational drug use (RDU), marijuana (THC), alcohol use, and psychiatric history were initially investigated with a questionnaire prior to history and physical. Following an educational intervention, we reinterrogated patients for RDU and THC use, and revision of initial statement was documented. Variables affecting commencement of antiviral therapy were analysed with logistic regression. Results. Out of 153 patients, 140 (92%) answered the questionnaire. Intervention increased total yield by 6%, however, 39% (11/28) of those initially denying use revised their statement. Drug screening identified 9 more patients with RDU/THC use. Half of patients consuming alcohol were heavy drinkers, and psychiatric disease was identified in 54%. Only 73 (48%) of 139 patients eligible for antivirals received treatment. Multivariable analysis revealed that younger patients (OR = 1.04, 95% CI 1.01-1.08), and those testing positive on drug screen (OR = 0.41, 95% CI 0.19-0.92) were less likely to be treated. Denial by insurance and loss to follow-up were the most common reasons for not starting antiviral treatment. Conclusion. Substance abuse is highly prevalent among HCV patients, and it is difficult to tell prior from current users. Integral care of HCV patients should include a diligent screen for substance abuse and rehabilitation referral, aiming to increase the pool of patients eligible for antiviral therapy. This can only be achieved through a multidisciplinary approach.


REFERENCES

  1. MMWR Morb Mortal Wkly Rep. Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. Centres For Disease Control And Prevention (CDC) 2013; 10: 362-5.

  2. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, et al. Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. Clin Infect Dis 2013; 57: S80-9.

  3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.

  4. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, Hamdounia SB, et al. Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006-2012. Clin Infect Dis 2014; 59: 1411-9.

  5. Suk KT, Mederacke I, Gwak GY, Cho SW, Adeyemi A, Friedman R, Schwabe RF. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut 2016; 65: 1721-32.

  6. Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, et al. Daily Canna bis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C. Gastroenterology 2008; 134: 432-9.

  7. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.

  8. Khan KN, Yatsuhashi H. Effect of Alcohol Consumption on the Progression of Hepatitis C Virus Infection and Risk of Hepatocellular Carcinoma in Japanese Patients. Alcohol Alcohol 2000; 35: 286-95.

  9. Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry 1988; 45: 1023-31.

  10. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry 1985; 42: 1067-71.

  11. Rounsaville BJ, Weissman MM, Kleber H, Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982; 39: 161-8.

  12. Weissman MM, Myers JK, Harding PS. Prevalence and psychiatric heterogeneity of alcoholism in a United States urban community. J Stud Alcohol 1980; 41: 672-81.

  13. Comorbid Drug Abuse and Mental Illness - comorbid.pdf [Internet]. [cited 2016 Nov 2]. Available from: https://www.apa.org/about/gr/issues/substance-abuse/comorbid.pdf

  14. Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43: 1276-92.

  15. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels. J Infect Dis 2013; 15: S19-25.

  16. Grebely J, Bruggmann P, Treloar C, Byrne J, Rhodes T, Dore GJ. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26: 893-8.

  17. Edlin BR. Prevention and Treatment of Hepatitis C in Injection Drug Users. Hepatol Baltim Md 2002; 36: S210-9.

  18. Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol 2013; 19: 7846-51.

  19. Grebely J, Dore G. What Is Killing People with Hepatitis C Virus Infection? Semin Liver Dis 2011; 31: 331-9.

  20. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-44.

  21. Alcohol Facts and Statistics | National Institute on Alcohol Abuse and Alcoholism (NIAAA) [Internet]. [cited 2016 Sep 22]. Available from: https: //www.niaaa.nih.gov/alcoholhealth/ overview-alcohol-consumption/alcohol-facts-and-statistics

  22. Skeff KM. Restructuring the patient’s history: enhancing the consultant's role as a teacher. Gastroenterology 2014; 147: 1208-11.

  23. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Patterns of Prescription Drug Misuse among Young Injection Drug Users. J Urban Health Bull N Y Acad Med 2012; 89: 1004-16.

  24. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into Prescription Opioid Misuse among Young Injection Drug Users. Int J Drug Policy 2012; 23: 37-44.

  25. Holtzman D, Barry V, Ouellet LJ, Jarlais DCD, Vlahov D, Golub ET, Hudson SM, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med 2009; 49: 68-73.

  26. Cheng T, Wood E, Nguyen P, Montaner J, Kerr T, DeBeck K. Crack Pipe Sharing Among Street-Involved Youth in a Canadian Setting. Drug Alcohol Rev 2015; 34: 259-66.

  27. Caiaffa WT, Zocratto KF, Osimani ML, Martínez PL, Radulich G, Latorre L, Muzzio E, et al. Hepatitis C virus among non-injecting cocaine users (NICUs) in South America: can injectors be a bridge? Addiction 2011; 106: 143-51.

  28. Porter J, Bonilla L. Crack users’ cracked lips: an additional HIV risk factor. Am J Public Health 1993; 83: 1490-1.

  29. Koblin BA, Factor SH, Wu Y, et al. Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol 2003; 70: 387-90.

  30. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Jarlais DCD, Flom PL, Strauss, S. Non-injection drug use and Hepatitis C Virus: A systematic review. Drug Alcohol Depend 2007; 89: 1-12.

  31. Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. Int J Drug Policy 2014; 25: 179-82.

  32. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J 2013; 10: 7.

  33. Dolganiuc A. Alcohol and Viral Hepatitis. Alcohol Res Curr Rev 2015; 37: 299-309.

  34. Anderson BJ, Gogineni A, Charuvastra A, Longabaugh R, Stein MD. Adverse drinking consequences among alcohol abusing intravenous drug users. Alcohol Clin Exp Res 2001; 25: 41-5.

  35. Campbell JV, Hagan H, Latka MH, Garfein RS, Golub ET, Coady MH, Thomas DL, et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006; 81: 259-65.

  36. Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, Kapadia F, et al. Eligibility for Treatment of Hepatitis C Virus Infection among Young Injection Drug Users in 3 US Cities. Clin Infect Dis 2006; 42: 669-72.

  37. Takase S, Takada N, Sawada M, Tsutsumi M, Takada A. Relationship between alcoholic liver disease and HCV infection. Alcohol Alcohol Oxf Oxfs Suppl 1993; 1A: 77-84.

  38. Askgaard G, Grřnbćk M, Kjćr MS, Tjřnneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol 2015; 62: 1061-7.

  39. Zduniak K, Ziólkowski P, Regnell P, Tollet-Egnell P, Ĺkesson L, Cooper Me. Immunohistochemical analysis of cannabinoid receptor 1 expression in steatotic rat livers. Exp Ther Med 2016; 11: 1227-30.

  40. Denaës T, Lodder J, Chobert M-N, Ruiz I, Pawlotsky J-M, Lotersztajn S, Teixeira-Clerc F. The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway. Sci Rep 2016; 6: 28806. Published online 2016 Jun 27.

  41. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, Tran-Van-Nhieu J, et al. CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 2008; 153: 286-9.

  42. Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani E-S, Pawlotsky JM, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71.

  43. Gonzalez HC, Duarte-Rojo A. Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes. Curr Gastroenterol Rep 2016; 18: 32.

  44. Alcoholism and Psychiatric Disorders [Internet]. [cited 2016 Nov 2]. Available from: http: //pubs.niaaa.nih.gov

  45. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995; 56: 19-24.

  46. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235.

  47. Smolders EJ, de Kanter CTMM, de Knegt RJ, van der Valk M, Drenth JPH, Burger DM. Drug-Drug Interactions Between Direct- Acting Antivirals and Psychoactive Medications. Clin Pharmacokinet 2016; 55: 1471-94.

  48. Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P. Are Targeted Treatment Recommendations in Chronic Hepatitis C Tailored to Diagnostic Methods of Fibrosis? J Hepatol 2017; 66: 304-12.

  49. Ho S, Brau N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol 2015; 13: 2005-14.

  50. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol 2017; 66: 19-27.




2020     |     www.medigraphic.com